Which hematology/oncology patients are high priority for ambulatory clinical pharmacist review? A three-round Delphi survey by the National Comprehensive Cancer Network

Author:

Booth Jennifer P12ORCID,Kennerly-Shah Julie M1,Kelley Lindsey R3,Capozzi Donna4,Prescott Hillary A5,Soefje Scott A6ORCID,Pace Makala B7,Barbour Sally Y8,Tizon Ricky F9,DeVincenzo Sarah10,Carnes Cynthia A2,Neidecker Marjorie V2

Affiliation:

1. Department of Pharmacy, The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH, USA

2. The Ohio State University—College of Pharmacy, Columbus, OH, USA

3. Department of Pharmacy, Michigan Medicine, Ann Arbor, MI, USA

4. Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

5. Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA

6. Department of Pharmacy, Mayo Clinic, Rochester, MN, USA

7. Department of Pharmacy, Huntsman Cancer Institute, Salt Lake City, UT, USA

8. Department of Pharmacy, Duke Cancer Institute, Durham, NC, USA

9. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA

10. Department of Pharmacy, National Comprehensive Cancer Network, Plymouth Meeting, PA, USA

Abstract

Introduction Prioritization and acuity tools have been leveraged to facilitate targeted and efficient clinical pharmacist interventions. However, there is a lack of established pharmacy-specific acuity factors in the ambulatory hematology/oncology setting. Therefore, National Comprehensive Cancer Network's Pharmacy Directors Forum conducted a survey to establish consensus on acuity factors associated with hematology/oncology patients that are high priority for ambulatory clinical pharmacist review. Methods A three-round electronic Delphi survey was conducted. During the first round, respondents were asked an open-ended question to suggest acuity factors based on their expert opinion. Respondents were then asked in the second round to agree or disagree with the compiled acuity factors, in which those with ≥75% agreement were included in the third round. The final consensus was defined as a mean score ≥3.33 on a modified 4-point Likert scale (4 = strongly agree, 1 = strongly disagree) during the third round. Results A total of 124 hematology/oncology clinical pharmacists completed the first round of the Delphi survey (invitation response rate, 36.7%), of which 103 completed the second round (response rate, 83.1%) and 84 the third round (response rate, 67.7%). A final consensus was achieved for 18 acuity factors. Acuity factors were identified in the following themes: antineoplastic regimen characteristics, drug interactions, organ dysfunction, pharmacogenomics, recent discharge, laboratory parameters, and treatment-related toxicities. Conclusions This Delphi panel of 124 clinical pharmacists achieved consensus on 18 acuity factors that would identify a hematology/oncology patient as a high priority for ambulatory clinical pharmacist review. The research team envisions incorporating these acuity factors into a pharmacy-specific electronic scoring tool.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Oncology

Reference17 articles.

1. null

2. Hematology/Oncology Pharmacy Association. Further defining the scope of hematology/oncology pharmacy practice. 2019. Available from: https://www.hoparx.org/images/hopa/resource-library/guidelines-standards/HOPA18_Scope-2_Web2.pdf

3. Impact of clinical pharmacists in outpatient oncology practices: A review

4. Demonstrating the value of the oncology pharmacist within the healthcare team

5. Medical Care Costs Associated with Cancer Survivorship in the United States

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3